FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Lipo-C

Lipotropic Complex / MIC Injection

Beauty & Skincare

Lipo-C (Lipotropic Compound) is an injectable formulation combining methionine, inositol, and choline (MIC) with B-complex vitamins (typically B1, B2, B5, B6, and B12), designed to support fat metabolism, liver function, and energy production. It is commonly prescribed by weight loss clinics and functional medicine practitioners as an adjunct to diet and exercise programs. While not a peptide in the strict biochemical sense, Lipo-C is frequently categorized alongside peptide therapies in clinical weight management protocols.

作用機序

Lipotropic injection containing methionine, inositol, choline, and commonly supplemented with L-carnitine, B12, and B-complex vitamins. Enhances hepatic fat metabolism, supports methylation pathways, and promotes bile flow for improved lipid processing.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Protocols typically use 1ml intramuscular injection weekly. Some protocols use twice weekly during active weight management. Often combined with dietary and exercise programs.

研究ノート

Clinical Research Status

Lipotropic injections have been used in clinical practice for decades, though high-quality randomized controlled trials specifically evaluating the MIC + B-vitamin combination for fat loss are limited. Individual components have established biochemical roles in fat metabolism: methionine as a lipotropic amino acid, inositol as a secondary messenger in insulin signaling, and choline as essential for VLDL assembly and hepatic fat export. The combination is prescribed under physician supervision at compounding pharmacies but is not FDA-approved as a specific weight loss drug.

Key Published Findings

Methionine serves as a methyl donor essential for phosphatidylcholine synthesis and fat mobilization from hepatocytes, with deficiency directly linked to hepatic steatosis in animal models. Inositol research demonstrates improved insulin sensitivity and reduced body weight in polycystic ovary syndrome (PCOS) patients at doses of 2-4g daily in multiple randomized trials. Choline deficiency is associated with fatty liver disease, and adequate choline status supports VLDL secretion necessary for hepatic fat clearance.

Safety Profile

MIC injections are generally well-tolerated, with the most common side effects being injection site soreness, mild gastrointestinal discomfort, and occasional headache. B-vitamin components are water-soluble with wide therapeutic margins, though B6 neurotoxicity is possible at very high chronic doses. Methionine supplementation should be used cautiously in individuals with elevated homocysteine levels unless adequate B6, B12, and folate are co-administered to support the methylation cycle.

Comparison to Related Compounds

Lipo-C differs from single-agent weight loss peptides like semaglutide or tirzepatide by targeting hepatic fat metabolism rather than appetite suppression or incretin signaling. Compared to L-carnitine injections which facilitate mitochondrial fatty acid transport, MIC components address earlier steps in fat mobilization and export from the liver. Injectable administration provides higher bioavailability than oral supplements, particularly for B12 in patients with absorption issues, though the clinical significance of this advantage for the other components is debated.

Community Observations

Users at weight loss clinics typically receive weekly or twice-weekly injections as part of comprehensive programs including caloric restriction and exercise. Many report increased energy levels within hours of injection, likely attributable to B-vitamin components rather than fat metabolism effects which would be more gradual. Results are generally described as supportive rather than dramatic, with most practitioners positioning Lipo-C as a metabolic optimization tool rather than a primary weight loss intervention.

半減期

N/A (vitamin complex)

再構成

Pre-mixed solution (no reconstitution required)

保存

乾燥粉末

Refrigerate 2-8C. Protect from light.

再溶解

Refrigerate 2-8C. Stable for 90 days.

米国法的状況

Supplement/compounded medication

また知られる名前

Lipotropic ComplexMIC Injection

よくある質問

Lipo-Cとは何ですか?

Lipo-C (Lipotropic Compound) is an injectable formulation combining methionine, inositol, and choline (MIC) with B-complex vitamins (typically B1, B2, B5, B6, and B12), designed to support fat metabolism, liver function, and energy production. It is commonly prescribed by weight loss clinics and functional medicine practitioners as an adjunct to diet and exercise programs. While not a peptide in the strict biochemical sense, Lipo-C is frequently categorized alongside peptide therapies in clinical weight management protocols.

Lipo-Cはどのように作用しますか?

Lipotropic injection containing methionine, inositol, choline, and commonly supplemented with L-carnitine, B12, and B-complex vitamins. Enhances hepatic fat metabolism, supports methylation pathways, and promotes bile flow for improved lipid processing.

Lipo-Cの米国での規制状況は?

Supplement/compounded medication

Lipo-Cの半減期は?

N/A (vitamin complex)

Lipo-Cの別名は?

Lipotropic Complex, MIC Injection

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む